Mimedx (MDXG) Net Margin (2011 - 2026)
Mimedx recorded quarterly Net Margin of 18.41% in Q1 2026, down 329.95% quarter-over-quarter from 8.01% in Q4 2024.
Mimedx's Net Margin history runs 15 years deep, the most recent figure standing at 18.41% for Q1 2026.
- In Q1 2026, Net Margin changed N/A year-over-year to 18.41%; the TTM figure through Mar 2026 stood at 2.79% (down 1214.0% YoY), while the FY2025 annual figure was 11.6%, down 43.0% from the prior year.
- Net Margin came in at 18.41% for Q1 2026 at Mimedx, down from 8.01% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 51.63% in Q4 2023 to a low of 20.5% in Q1 2022.
- A 4-year average of 3.94% and a median of 8.65% in 2023 frame the typical range for Net Margin.
- Across the five-year window, Net Margin surged 4069 bps in 2023 and tumbled 4362 bps in 2024, its largest moves.
- Mimedx's Net Margin stood at 10.94% in 2022, then surged by 372 bps to 51.63% in 2023, then slumped by 84 bps to 8.01% in 2024, then plunged by 330 bps to 18.41% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 18.41%, 8.01%, and 9.37% for Q1 2026, Q4 2024, and Q3 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.82% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 34.53% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 20.17% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 17.65% |
| 10 | Mimedx | 530.69 Mn | 370.92 Mn | 41.62 Mn | -18.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.41% |
| Dec 31, 2024 | 8.01% |
| Sep 30, 2024 | 9.37% |
| Jun 30, 2024 | 20.21% |
| Mar 31, 2024 | 10.70% |
| Dec 31, 2023 | 51.63% |
| Sep 30, 2023 | 8.65% |
| Jun 30, 2023 | 9.26% |
| Mar 31, 2023 | -5.06% |
| Dec 31, 2022 | 10.94% |
| Sep 30, 2022 | -14.92% |
| Jun 30, 2022 | -18.68% |
| Mar 31, 2022 | -20.50% |
| Dec 31, 2021 | -2.75% |
| Sep 30, 2021 | -6.20% |
| Jun 30, 2021 | -4.81% |
| Mar 31, 2021 | -16.43% |
| Dec 31, 2020 | -26.35% |
| Sep 30, 2020 | -80.84% |
| Jun 30, 2020 | -15.78% |
| Mar 31, 2020 | -7.81% |
| Dec 31, 2019 | -9.79% |
| Sep 30, 2019 | 13.93% |
| Jun 30, 2019 | -25.52% |
| Mar 31, 2019 | -19.94% |
| Dec 31, 2018 | -39.12% |
| Sep 30, 2018 | -0.20% |
| Jun 30, 2018 | 1.89% |
| Mar 31, 2018 | 5.49% |
| Dec 31, 2017 | 10.67% |
| Sep 30, 2017 | 16.16% |
| Jun 30, 2017 | 7.56% |
| Mar 31, 2017 | 8.37% |
| Dec 31, 2016 | -8.73% |
| Sep 30, 2016 | 5.15% |
| Jun 30, 2016 | 3.44% |
| Mar 31, 2016 | 2.24% |
| Dec 31, 2015 | 25.81% |
| Sep 30, 2015 | 13.37% |
| Jun 30, 2015 | 11.89% |
| Mar 31, 2015 | 10.03% |
| Dec 31, 2014 | 9.69% |
| Sep 30, 2014 | 11.04% |
| Jun 30, 2014 | -1.53% |
| Mar 31, 2014 | -4.71% |
| Dec 31, 2013 | -7.93% |
| Sep 30, 2013 | -1.91% |
| Jun 30, 2013 | -5.60% |
| Mar 31, 2013 | -14.02% |
| Dec 31, 2012 | -15.28% |
| Sep 30, 2012 | -53.05% |
| Jun 30, 2012 | -15.23% |
| Mar 31, 2012 | -29.51% |
| Dec 31, 2011 | -97.79% |
| Sep 30, 2011 | -82.05% |
| Jun 30, 2011 | -129.76% |
| Mar 31, 2011 | -320.81% |